Rapid progression of disease following ibrutinib discontinuation in patients with chronic lymphocytic leukemia.
Paul J. Hampel(Mayo Clinic), Sameer A. Parikh(Mayo Clinic), Tait D. Shanafelt(Mayo Clinic), Deborah A. Bowen(Mayo Clinic in Arizona), Amie Fonder, Susan M. Schwager(Mayo Clinic in Arizona), Timothy G. Call(Mayo Clinic), Saad S. Kenderian(Mayo Clinic in Arizona), Susan L. Slager(Mayo Clinic), Wei Ding(Mayo Clinic), Eli Muchtar(Mayo Clinic), Kari G. Chaffee(Mayo Clinic in Florida), Neil E. Kay(Mayo Clinic), José F. Leis(Mayo Clinic), Asher Chanan‐Khan(WinnMed)
Cited by 8
Related Papers
Executive Leadership and Physician Well-being
|Mayo Clinic Proceedings|2016|1.7k
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
|New England Journal of Medicine|2014|1.6k
Changes in Burnout and Satisfaction With Work-Life Integration in Physicians and the General US Working Population Between 2011 and 2017
|Mayo Clinic Proceedings|2019|903
Ibrutinib–Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2019|735
Systematic Review and Meta-Analysis of the Efficacy of Appropriate Empiric Antibiotic Therapy for Sepsis
|Antimicrobial Agents and Chemotherapy|2010|727